

(FILE 'HOME' ENTERED AT 23:30:17 ON 11 MAY 2006)

FILE 'REGISTRY' ENTERED AT 23:30:37 ON 11 MAY 2006

L1 122 S [KY]L.VVGA[DVCARS]GVGKS/SQSP  
L2 0 S YLVVVGA[DVCARS]GVGKS/SQSP  
L3 0 S [KY]L[-V]VVGA[DVCARS]GVGKS/SQSP

FILE 'DGENE' ENTERED AT 23:33:29 ON 11 MAY 2006

RUN GETSEQ

-----

L4 RUN STATEMENT CREATED  
RUN GETSEQ

-----

L5 RUN STATEMENT CREATED  
RUN GETSEQ

-----

L6 RUN STATEMENT CREATED  
L7 14 S L6 AND AD<19960419

FILE 'REGISTRY' ENTERED AT 23:37:56 ON 11 MAY 2006

L8 58 S L1 AND SQL<51  
L9 56 S L1 AND SQL<36

FILE 'HCAPLUS' ENTERED AT 23:39:08 ON 11 MAY 2006

L10 38 S L9  
L11 3 S L10 AND AD<19960419  
L12 17 S L10 AND PY<1997  
L13 18 S L11 OR L12

FILE 'REGISTRY' ENTERED AT 23:44:28 ON 11 MAY 2006

L14 1 S L1 AND (286948-89-8)/RN  
L15 1 S L1 AND (185447-10-3)/RN  
L16 1 S L1 AND (162550-85-8)/RN  
L17 1 S L1 AND (185303-60-0)/RN  
L18 1 S L1 AND (185351-64-8)/RN  
L19 1 S L1 AND (185438-20-4)/RN  
L20 1 S L1 AND (177352-90-8)/RN  
L21 1 S L1 AND (177352-91-9)/RN  
L22 1 S L1 AND (177352-92-0)/RN  
L23 1 S L1 AND (177352-93-1)/RN  
L24 1 S L1 AND (177352-94-2)/RN  
L25 0 S L1 AND (1773692-72-3)/RN  
L26 1 S L1 AND (173692-72-3)/RN  
L27 1 S L1 AND (162550-83-6)/RN  
L28 1 S L1 AND (162550-84-7)/RN  
L29 1 S L1 AND (162550-85-8)/RN  
L30 1 S L1 AND (145019-86-9)/RN  
L31 0 S L1 AND (145019-89-1)/RN  
L32 1 S L1 AND (145019-88-1)/RN  
L33 1 S L1 AND (145019-89-2)/RN  
L34 1 S L1 AND (145019-90-5)/RN  
L35 1 S L1 AND (145019-91-6)/RN  
L36 1 S L1 AND (145019-92-7)/RN  
L37 1 S L1 AND (158398-77-7)/RN  
L38 1 S L1 AND (145019-88-1)/RN  
L39 1 S L1 AND (145019-86-9)/RN  
L40 1 S L1 AND (121669-45-2)/RN  
L41 1 S L1 AND (119386-65-1)/RN  
L42 1 S L1 AND (91574-04-8)/RN  
L43 1 S L1 AND (91574-05-9)/RN  
L44 1 S L1 AND (97229-55-5)/RN  
L45 1 S L1 AND (91574-04-8)/RN  
L46 1 S L1 AND (91574-05-9)/R

d hitrn tot

L13 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~286948-89-8~~

RL: PRP (Properties)

(unclaimed sequence; adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity)

L13 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~185447-10-3~~

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antigen-presenting function of human peritoneum mesothelial cells isolated from human pancreatic carcinoma after mutant ras peptide vaccination)

L13 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~185447-10-3~~

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(p21 ras peptide vaccination of humans with pancreatic adenocarcinoma results in induction of T cells specific for ras peptides and HLA class II mols.)

L13 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~162550-85-8~~ ~~185303-60-0~~ ~~185351-64-8~~

~~185438-20-4~~

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(comparison of linear and branched peptide forms (MAPs) in induction of T helper responses to point-mutated ras immunogens)

L13 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~177352-90-8~~ ~~177352-91-9~~ ~~177352-92-0~~

~~177352-93-1~~ ~~177352-94-2~~

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(some mutated Ras- and p53-derived peptides could be tumor-specific antigens recognized by T cells in an HLA-DR-specific manner (Erratum))

L13 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~177352-90-8~~ ~~177352-91-9~~ ~~177352-92-0~~

~~177352-93-1~~ ~~177352-94-2~~

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(some mutated Ras- and p53-derived peptides could be tumor-specific antigens recognized by T cells in an HLA-DR-specific manner)

L13 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~173692-72-3~~

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses)

L13 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN

IT ~~162550-85-8~~

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(cytolytic response to tumor expressing p21ras mutation by CD4+ Th1 helper lymphocyte)

L13 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~162550-83-6~~ ~~162550-84-7~~ ~~162550-85-8~~  
RL: PRP (Properties)  
(induction of human cytotoxic T cells directed against point-mutated p21Ras-derived synthetic peptides)

L13 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~145019-86-9~~ ~~145019-88-1~~ ~~145019-89-2~~  
~~145019-90-5~~ ~~145019-91-6~~ ~~145019-92-7~~  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(binding of ras oncogene peptides to purified HLA-DQ and -DR antigens)

L13 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~158398-77-7~~  
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(Ras-derived; mouse cytotoxic T-cell MHC class I-unrestricted recognition of)

L13 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~145019-88-1~~  
RL: BIOL (Biological study)  
(T-cells of human recognition of, of p21 ras protein, HLA-DR and -DP and -DQ antigen restriction in)

L13 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~145019-86-9~~ ~~145019-88-1~~ ~~145019-89-2~~  
~~145019-90-5~~ ~~145019-91-6~~ ~~145019-92-7~~  
RL: BIOL (Biological study)  
(T-cell immunity to oncogene protein stimulation by)

L13 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~121669-45-2P~~  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and conformation of and ATP and GTP binding by)

L13 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~121669-45-2P~~  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, p21 ras protein conformation and GTP hydrolysis in relation to)

L13 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~119386-65-1~~  
RL: PRP (Properties)  
(conformation of, protein p21 nucleotide-binding region in relation to)

L13 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~91574-04-8~~ ~~91574-05-9~~ ~~91574-05-5~~  
RL: BIOL (Biological study)  
(antibodies to, from oncoprotein, specificity of)

L13 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2006 ACS on STN  
IT ~~91574-04-8~~ ~~91574-05-9~~  
RL: ANST (Analytical study)  
(antibodies to, for cancer diagnosis and treatment in humans)

d sqide tot

L7 ANSWER 1 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN ADM96361 peptide DGENE  
AA 2 A; 0 R; 1 N; 2 D; 0 B; 0 C; 2 Q; 3 E; 0 Z; 3 G; 1 H; 3 I; 3 L; 2 K; 1  
M; 1 F; 1 P; 1 S; 3 T; 0 W; 2 Y; 6 V; 0 Others

SQL 37

SEQ

1 mteyklvvvg avgvgksalt iqliqnhfvd eydptie  
=====

HITS AT: 5-17

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	note "Wild type Gly subsituted by Val"

L7 ANSWER 2 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAW00572 peptide DGENE  
AA 2 A; 0 R; 0 N; 0 D; 0 B; 0 C; 0 Q; 0 E; 0 Z; 3 G; 0 H; 1 I; 2  
L; 2 K; 0 M; 0 F; 0 P; 1 S; 1 T; 0 W; 0 Y; 5 V; 0 Others

SQL 17

SEQ

1 klvvvgavgv gksalti  
=====

HITS AT: 1-13

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	8	note "G12V mutation"

L7 ANSWER 3 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAW00569 peptide DGENE  
AA 2 A; 1 R; 0 N; 0 D; 0 B; 0 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 1 S; 2 T; 0 W; 1 Y; 4 V; 0 Others

SQL 25

SEQ

1 mteyklvvvg argvgksalt iqliq  
=====

HITS AT: 5-17

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	note "G12R mutation"

L7 ANSWER 4 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAW00568 peptide DGENE  
AA 2 A; 0 R; 0 N; 0 D; 0 B; 0 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 1 S; 2 T; 0 W; 1 Y; 5 V; 0 Others

SQL 25

SEQ

1 mteyklvvvg avgvgksalt iqliq

HITS AT: 5-17

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	note "G12V mutation"

L7 ANSWER 5 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAW00573 peptide DGENE  
AA 2 A; 1 R; 0 N; 0 D; 0 B; 0 C; 0 Q; 0 E; 0 Z; 3 G; 0 H; 1 I; 2  
L; 2 K; 0 M; 0 F; 0 P; 1 S; 1 T; 0 W; 0 Y; 4 V; 0 Others  
SQL 17  
SEQ

1 klvyvgargv gksalti

HITS AT: 1-13

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	8	note "G12R mutation"

L7 ANSWER 6 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAR26740 peptide DGENE  
AA 2 A; 0 R; 0 N; 0 D; 0 B; 0 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 2 S; 2 T; 0 W; 1 Y; 4 V; 0 Others  
SQL 25  
SEQ

1 mteyklvvvg asgvgsalt iqliq

HITS AT: 5-17

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	label mutation note "Gly -> Ser; see CC"

L7 ANSWER 7 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAR26738 peptide DGENE  
AA 2 A; 1 R; 0 N; 0 D; 0 B; 0 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 1 S; 2 T; 0 W; 1 Y; 4 V; 0 Others  
SQL 25  
SEQ

1 mteyklvvvg argvgksalt iqliq

HITS AT: 5-17

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	label mutation

| |note |"Gly -> Arg; see CC"

L7 ANSWER 8 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAR26739 peptide DGENE  
AA 3 A; 0 R; 0 N; 0 D; 0 B; 0 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 1 S; 2 T; 0 W; 1 Y; 4 V; 0 Others

SQL 25

SEQ

1 mteyklvvvg aagvgksalt iqliq

=====

HITS AT: 5-17

#### FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	label mutation
		note  "Gly -> Ala; see CC"

L7 ANSWER 9 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAR26736 peptide DGENE  
AA 2 A; 0 R; 0 N; 0 D; 0 B; 0 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 1 S; 2 T; 0 W; 1 Y; 5 V; 0 Others

SQL 25

SEQ

1 mteyklvvvg avgvgksalt iqliq

=====

HITS AT: 5-17

#### FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	label mutation
		note  "Gly -> Val; see CC"

L7 ANSWER 10 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAR26742 peptide DGENE  
AA 2 A; 0 R; 0 N; 1 D; 0 B; 0 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 1 S; 2 T; 0 W; 1 Y; 4 V; 0 Others

SQL 25

SEQ

1 mteyklvvvg adgvgksalt iqliq

=====

HITS AT: 5-17

#### FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	label mutation
		note  "Gly -> Asp; see CC"

L7 ANSWER 11 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
AN AAR26741 peptide DGENE  
AA 2 A; 0 R; 0 N; 0 D; 0 B; 1 C; 2 Q; 1 E; 0 Z; 3 G; 0 H; 2 I; 3  
L; 2 K; 1 M; 0 F; 0 P; 1 S; 2 T; 0 W; 1 Y; 4 V; 0 Others

SQL 25  
 SEQ  
 1 mteyklvvvg acgvgksalt iqliq  
 =====  
 HITS AT: 5-17

FEATURE TABLE:

Key	Location	Qualifier
Misc-difference	12	label mutation
		"Gly -> Cys; see CC"

L7 ANSWER 12 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
 AN AAP70530 protein DGENE  
 AA 2 A; 0 R; 0 N; 0 D; 0 B; 0 C; 0 Q; 1 E; 0 Z; 3 G; 0 H; 0 I; 1  
 L; 2 K; 1 M; 0 F; 0 P; 2 S; 1 T; 0 W; 1 Y; 4 V; 0 Others  
 SQL 18  
 SEQ

1 mteyklvvvg asgvgksa  
 =====  
 HITS AT: 5-17

L7 ANSWER 13 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
 AN AAP50682 Protein DGENE  
 AA 8 A; 8 R; 4 N; 13 D; 0 B; 4 C; 9 Q; 11 E; 0 Z; 9 G; 3 H; 10 I;  
 10 L; 9 K; 4 M; 5 F; 4 P; 8 S; 11 T; 0 W; 7 Y; 13 V; 0 Others  
 SQL 150  
 SEQ

1 mteyklvvvg acgvgksalt iqliqnhfvd eydptiedsy rkqvvidget  
 =====  
 51 clldildtag qeysamrdq ymrtgegflc vfainntksf edihhyreqi  
 101 krkdsedvp mvlvgnkcdl psrtvdtkqa qdlarsygip fietsaktrq  
 HITS AT: 5-17

L7 ANSWER 14 OF 14 DGENE COPYRIGHT 2006 The Thomson Corp on STN  
 AN AAP40581 Protein DGENE  
 AA 2 A; 0 R; 1 N; 2 D; 0 B; 0 C; 2 Q; 3 E; 0 Z; 3 G; 1 H; 3 I; 3  
 L; 2 K; 1 M; 0 F; 1 P; 1 S; 3 T; 0 W; 2 Y; 6 V; 0 Others  
 SQL 36  
 SEQ

1 mteyklvvvg avgvgksalt iqliqnhvde ydptie  
 =====  
 HITS AT: 5-17